Alpha-GPC
L-alpha-glycerylphosphorylcholine
A choline phospholipid with preliminary cognitive and power signals — shadowed by a stroke-risk caution.
Evidence tier
Preliminary
Research weight
Citations
14 verified / 14
Classification
Nootropic
❝
What the evidence says. Early or small human trials; promising but not yet conclusive.
What is Alpha-GPC?
Alpha-GPC (L-alpha-glycerylphosphorylcholine) is a nootropic used for may modestly improve cognition in adult-onset dementia, especially when added to cholinesterase inhibitors (clinical populations, not healthy users).. NutriDex grades the human evidence as Preliminary. Alpha-GPC (choline alphoscerate) is a phospholipid choline source marketed as a nootropic and pre-workout ingredient. The strongest human data are in clinical dementia populations, where a 2023 meta-analysis of 7 RCTs (861 participants) found improved cognition, particularly when combined with donepezil; benefit in healthy people rests on small, short-term studies showing acute gains on tasks like the Stroop test. Evidence for athletic power output is genuinely mixed, with some trials showing greater peak force and others showing no effect. A critical safety signal comes from a 2021 South Korean cohort of over 12 million adults, which linked alpha-GPC use to a roughly 43–46% higher 10-year stroke risk in a dose-dependent manner, plausibly via choline-derived TMAO. Notably, other Korean cohort data suggest a lower risk of dementia conversion in MCI patients, so the overall risk-benefit picture is unsettled. On balance the evidence is preliminary, and the cardiovascular caution should be weighed seriously, especially by older adults or those with vascular risk factors.
Purported Benefits
✓May modestly improve cognition in adult-onset dementia, especially when added to cholinesterase inhibitors (clinical populations, not healthy users).
✓Single acute doses have improved processing speed/cognitive interference (Stroop) in small studies of healthy adults — short-term and not yet replicated at scale.
✓Mixed, preliminary signals for muscle force/power output; some trials show greater peak force, others show no effect on power.
✓Serves as a bioavailable choline donor that crosses the blood-brain barrier and supports acetylcholine synthesis.
✓Acutely raises growth hormone secretion in some studies, though clinical relevance is unproven.
Evidence by outcome
The same supplement can be well-proven for one use and unproven for another — here is the human evidence graded outcome by outcome.
| Outcome | Evidence | Effect | Studies |
|---|---|---|---|
| Cognition in adult-onset dementia (esp. with donepezil)2023 meta-analysis of 7 RCTs shows MMSE/ADAS-Cog gains, strongest as add-on to cholinesterase inhibitors, not in healthy users. | Moderate | ↑ benefit · moderate | 3 |
| Acute processing speed / cognitive control (Stroop) in healthy adultsSingle acute-dose crossover RCT improved Stroop; short-term, not replicated at scale. | Preliminary | ↑ benefit · small | 1 |
| Muscle force / power outputSmall trials conflict: one showed greater isometric peak force, others no effect on power. | Mixed | ↔ mixed | 2 |
| 10-year stroke riskLarge Korean cohort (12M adults) links use to ~43-46% higher dose-dependent stroke risk; observational, plausibly via TMAO. | Moderate | ⚠ risk · moderate | 2 |
Dosing & Compounds
Typical Dose
300–600 mg/day for performance/cognition; 1,200 mg/day (often divided) used in dementia trials. Acute pre-exercise/pre-task doses ~300–600 mg.
Active Compounds
Safety & Cautions
A large 2021 South Korean cohort linked alpha-GPC use to a dose-dependent ~43–46% increase in 10-year stroke risk (ischemic and hemorrhagic); causality is unproven and confounding is possible, but this is a serious caution — older adults and anyone with hypertension, atrial fibrillation, prior stroke/TIA, atherosclerosis, or other cardiovascular/cerebrovascular risk factors should be especially cautious and consult a clinician. The proposed mechanism is conversion of choline to TMAO, a metabolite tied to atherothrombosis. Common side effects are generally mild: headache, heartburn, dizziness, insomnia, and GI upset. Theoretical additive cholinergic effects mean caution with cholinergic drugs (e.g., cholinesterase inhibitors) and anticholinergics; relevance to anticoagulants/antiplatelets is unestablished but warrants medical advice given the stroke signal. Avoid in pregnancy and breastfeeding due to insufficient safety data. Not a substitute for prescribed therapy in dementia; use under medical supervision in clinical populations. Educational only — always check with your doctor or pharmacist before combining Alpha-GPC with any medicine.
Key Studies ★ 14 studies
Systematic review and meta-analysis
861 (7 RCTs + 1 cohort)
✓ PubMed
This 2023 meta-analysis found alpha-GPC improved cognition in adult-onset dementia, with better MMSE scores alone (MD 3.50) and added benefit on ADAS-Cog when combined with donepezil (MD −5.76).
Meta-analysis
Frontiers in Neurology 2025
✓ PubMed
Systematic review/meta-analysis of 3 RCTs (n=358) found choline alphoscerate improved clinical condition vs citicoline on the SCAG scale (WMD -3.92, 95% CI -7.41 to -0.42), with comparable dropout rates (OR 1.44, 95% CI 0.66-3.13).
Meta-analysis
Sagaro/Traini/Amenta 2023 (J Alzheimers Dis)
✓ Full text
Systematic review and meta-analysis concluded choline alphoscerate improves cognitive performance and may reduce cognitive decline in adult-onset cognitive dysfunction, including as add-on to donepezil.
Randomized crossover RCT
20 healthy resistance-trained men
✓ PubMed
In this 2024 randomized double-blind crossover trial, acute 315 mg and 630 mg doses significantly improved Stroop test performance versus placebo, indicating better processing speed/cognitive control.
RCT
Hwang 2024 (BMC Geriatrics)
✓ PubMed
In a 12-week double-blind RCT of 100 patients with amnestic mild cognitive impairment, choline alphoscerate reduced ADAS-cog by 2.34 points vs baseline (p<0.0001) and significantly outperformed placebo (p<0.05).
RCT
ASCOMALVA (Carotenuto et al.) 2017
✓ PubMed
Double-blind RCT in Alzheimer's disease with cerebrovascular injury: donepezil + choline alphoscerate significantly reduced behavioral and psychological symptoms (BPSD severity, NPI) and caregiver distress versus donepezil + placebo over follow-up.
RCT
Bellar, LeBlanc & Campbell 2015
✓ PubMed
Double-blind, placebo-controlled crossover (n=13 men). 6 days of 600 mg/day alpha-GPC significantly increased lower-body isometric mid-thigh pull peak force change (+98.8 N vs -39.0 N placebo, p=0.044); upper-body force trended higher but was non-significant (p=0.127).
Randomized controlled trials (mixed)
Trained athletes (small RCTs)
✓ PubMed
Across small randomized trials, alpha-GPC showed mixed effects on athletic performance — some reporting greater peak/isometric force, others finding no significant change in power output.
Review
Putri 2026
✓ PubMed
L-α-GPC in Cognitive Decline: Mechanisms and Clinical Evidence in Neurodegenerative Disorders
Review
Kang 2026
✓ PubMed
Nutritional and biological insights into natural α-glycerylphosphoryl derivatives (α-NGPs): a comprehensive review of α-GPA, α-GPC, α-GPE, α-GPI, and α-GPS
Review
Frontiers in Aging Neuroscience 2025
✓ Full text
Narrative review summarizing current human evidence concludes alpha-GPC may improve cognition in dementia but it remains uncertain whether it adds benefit over approved anti-dementia drugs.
Population-based cohort study
508,107 patients with mild cognitive impairment
✓ PubMed
This 2025 nationwide Korean cohort found alpha-GPC users had a modestly lower risk of conversion to Alzheimer's disease (HR 0.90) and vascular dementia (HR 0.83) versus non-users.
Retrospective cohort study
12,008,977 adults ≥50 (matched cohort 1,190,376)
✓ PubMed
In this 2021 South Korean population cohort, alpha-GPC use was associated with a 46% higher 10-year total stroke risk (aHR 1.46; matched aHR 1.43), with a dose-dependent trend rising to aHR 1.36 for >12 months of use.
Observational
Lee 2021 (JAMA Network Open)
✓ Full text
Retrospective cohort of 12,008,977 adults aged 50+ found alpha-GPC use associated with higher 10-year total stroke risk (aHR 1.48, 95% CI 1.43-1.52), with a dose-response rise to aHR 1.36 (95% CI 1.29-1.43) for >12 months of use.